SubQ vs IM Testosterone: Which Injection Is Better?

The injection method you choose for TRT affects more than just comfort. Subcutaneous and intramuscular injections differ in absorption rate, hormone stability, estradiol conversion, hematocrit impact, and long-term tissue effects. Most men default to intramuscular because that is what their clinic prescribed first. But the evidence increasingly favors subcutaneous for the majority of TRT patients.

Key Takeaways

• Subcutaneous injections achieve the same therapeutic testosterone levels as intramuscular, with more stable day-to-day levels
• SubQ produces lower estradiol and hematocrit spikes than IM due to slower, steadier absorption
• SubQ uses smaller needles (27-31 gauge), is virtually painless, and eliminates the risk of hitting nerves or blood vessels in muscle
• IM may still be preferred for high-volume injections (above 0.5 mL) or patients with very low body fat
• Most modern TRT clinics now offer subcutaneous protocols, and many have made it their default

What Each Method Actually Means

Intramuscular (IM) Injection

Intramuscular injection delivers testosterone directly into skeletal muscle tissue. The oil-based testosterone sits in a depot within the muscle fibers, where it absorbs into the bloodstream through the muscle's dense capillary network.

Common IM injection sites include the vastus lateralis (outer thigh), ventrogluteal (hip), and deltoid (shoulder). Needle length ranges from 1 to 1.5 inches with 23-25 gauge thickness, depending on the site and the patient's body composition.

IM injection has been the standard for testosterone replacement since the 1950s. It works. But "standard" does not mean "optimal."

Subcutaneous (SubQ) Injection

Subcutaneous injection delivers testosterone into the fat layer just beneath the skin. The testosterone depot sits in adipose tissue, where it absorbs more slowly through the smaller capillary network in fat compared to muscle.

SubQ injection sites include the abdomen (at least 2 inches from the navel), the love handle area, the upper outer thigh, and the back of the arm. Needle length is typically 1/4 to 1/2 inch with 27-31 gauge thickness -- the same insulin syringes diabetics use millions of times daily.

SubQ testosterone gained clinical traction in the 2010s and is now widely adopted by progressive TRT clinics. The FDA-approved Xyosted autoinjector (subcutaneous testosterone enanthate) further legitimized the route.

Pharmacokinetics: How Absorption Differs

This is where the methods diverge meaningfully.

IM Absorption Pattern

Intramuscular injection creates a rapid absorption curve. Testosterone levels spike within 24-48 hours of injection, often reaching supraphysiological peaks (above 1,500 ng/dL on standard doses), then decline steadily until the next injection.

A study measuring hormone profiles after intramuscular testosterone enanthate found that serum estradiol levels increased 1.7-fold within 24 hours of injection, driven by the testosterone spike overwhelming the aromatase enzyme system [1]. This peak-and-crash pattern is what drives many of the side effects men associate with TRT -- mood swings, acne flares, and water retention that fluctuate with their injection schedule.

SubQ Absorption Pattern

Subcutaneous injection creates a flatter absorption curve. Adipose tissue has a less dense capillary network than muscle, so testosterone absorbs more gradually. The result is lower peaks and higher troughs -- a narrower band of testosterone fluctuation throughout the injection cycle.

A 52-week study of 150 hypogonadal men using weekly subcutaneous testosterone enanthate found that 92.7% achieved average total testosterone of 300-1,100 ng/dL (mean 553 ng/dL), with "small peak and trough fluctuations" [2]. The researchers specifically noted the pharmacokinetic profile was steady, a direct contrast to the rollercoaster pattern seen with IM.

A separate study in patients receiving weekly subcutaneous testosterone cypionate confirmed that total and free testosterone levels "remained stable between injections" throughout the dosing interval [3]. This stability is the core pharmacokinetic advantage of SubQ delivery.

Blood Level Stability

Stability matters because your body responds not just to average testosterone levels but to the rate of change. Rapid swings in testosterone trigger:

• Estradiol spikes -- aromatase converts testosterone to estradiol proportionally to the peak, not the average
• Hematocrit surges -- erythropoiesis responds to supraphysiological peaks
• Mood instability -- neurosteroid levels fluctuate with testosterone
• Energy crashes -- the trough before your next injection feels worse when the peak was higher

The flatter SubQ curve addresses all four of these. Men who switch from weekly IM to SubQ at the same dose frequently report feeling "more even" -- not higher or lower, but more consistent day to day.

Estradiol and Hematocrit: The Safety Argument

This is where the data gets compelling.

A comparative study of 234 hypogonadal men treated with either intramuscular testosterone cypionate or subcutaneous testosterone enanthate (both at 100 mg weekly) found significant differences in secondary markers [4]:

• Estradiol: SubQ produced lower post-treatment estradiol levels than IM after adjusting for covariates
• Hematocrit: SubQ was associated with lower post-therapy hematocrit elevations than IM
• PSA: No significant difference between groups

The researchers concluded that subcutaneous testosterone enanthate "represents an effective testosterone delivery system with a potentially preferable safety profile over intramuscular testosterone cypionate."

This is not a minor distinction. Elevated hematocrit is the most common reason men are forced to reduce their TRT dose or donate blood. Elevated estradiol is the most common reason men are prescribed an aromatase inhibitor they may not need. If the injection route itself can reduce both of these problems without changing the dose, that is a meaningful clinical advantage.

For more on managing estradiol levels, see our guide on estradiol management on TRT.

Head-to-Head Comparison

Factor	Subcutaneous (SubQ)	Intramuscular (IM)
Needle gauge	27-31 gauge (insulin syringe)	23-25 gauge
Needle length	1/4 - 1/2 inch	1 - 1.5 inches
Pain level	Minimal to none	Mild to moderate
Injection sites	Abdomen, love handles, thigh fat, arm	Glutes, quads, delts, ventrogluteal
Absorption rate	Slower, more gradual	Faster, sharper peak
T level stability	More stable between injections	More peak-and-trough variation
Estradiol levels	Lower post-injection	Higher post-injection
Hematocrit impact	Lower elevation	Higher elevation
Max comfortable volume	0.3-0.5 mL per site	1-3 mL per site
Scar tissue risk	Lower (smaller needle, shallower)	Higher with repeated use
Nerve/vessel risk	Essentially zero	Small but present
Self-injection ease	Easy (abdomen accessible)	Harder for some sites (glutes)
FDA-approved route	Yes (Xyosted)	Yes (traditional standard)

Which Clinics Recommend Which Method

The clinic landscape has shifted significantly in the past three years.

Clinics defaulting to SubQ: Most modern telehealth TRT clinics now start patients on subcutaneous protocols. The smaller needles, easier self-administration, and better side effect profile align with the telehealth model where patients manage their own injections at home. If you are evaluating online TRT clinics, ask specifically about their injection protocols.

Clinics still using IM: Traditional urology practices and some older clinics continue prescribing intramuscular injections, often biweekly at higher doses. This is partly institutional inertia -- IM has decades of clinical precedent -- and partly because some physicians are unfamiliar with the SubQ data.

Clinics offering both: The best clinics let patients choose after explaining both options, then adjust based on lab results and patient preference. A study of patients originally on IM who were offered the switch found that all 22 patients who tried SubQ expressed a preference for it -- none wanted to go back to IM [5].

Practical Injection Guidance

SubQ Technique

Equipment: 0.5 mL or 1 mL insulin syringe, 27-31 gauge, 1/2 inch needle. No separate drawing needle needed for small volumes -- insulin syringes can draw directly from the vial, though it takes 30-60 seconds for viscous testosterone oil through a fine gauge.

Site preparation: Clean the injection site with an alcohol swab. Let it air dry completely.

Injection steps:

1. Pinch a fold of skin and fat between your thumb and index finger at the injection site
2. Insert the needle at a 45-90 degree angle (45 degrees for lean individuals, 90 degrees if you have adequate subcutaneous fat)
3. Inject slowly -- 10-15 seconds for the full volume
4. Release the skin fold and withdraw the needle
5. Apply gentle pressure with a cotton ball if there is any bleeding

Volume limit: Keep individual SubQ injections to 0.5 mL or less per site. If your weekly dose requires more volume, split it across two sites or increase your injection frequency.

Site rotation: Rotate between at least 4-6 sites to prevent lipohypertrophy (hard lumps in the fat). The abdomen alone provides ample real estate -- think of it as a clock face around your navel, with injection sites at 2, 4, 8, and 10 o'clock positions, each at least 2 inches from the navel. For a full site rotation strategy, see our managing injection sites guide.

IM Technique

Equipment: 1 mL or 3 mL luer-lock syringe. Drawing needle: 18-21 gauge, 1 inch. Injection needle: 23-25 gauge, 1-1.5 inches.

Preferred sites:

• Ventrogluteal (recommended): Place your palm on the greater trochanter, index finger on the anterior iliac crest, spread your middle finger toward the iliac crest -- inject in the V between your fingers. This site has the lowest nerve density and thickest muscle.
• Vastus lateralis (outer thigh): The outer middle third of the thigh. Easy to self-inject but has more nerve endings.
• Deltoid: Suitable for volumes under 1 mL. Convenient but limited by muscle size.

Injection steps:

1. Clean the site with an alcohol swab
2. Spread the skin taut with your non-dominant hand (Z-track technique: pull the skin to one side before inserting)
3. Insert the needle at 90 degrees in a smooth, dart-like motion
4. Aspirate briefly -- if blood appears, withdraw and try a different spot
5. Inject slowly over 10-20 seconds
6. Withdraw the needle and release the skin
7. Apply pressure with a cotton ball

For the complete step-by-step technique guide, see TRT injection technique guide.

When IM Might Still Be the Better Choice

SubQ wins for most TRT patients, but there are legitimate scenarios where intramuscular injection makes more sense:

High-volume doses. If your protocol requires more than 0.5 mL per injection and you inject once weekly, IM accommodates larger volumes more comfortably. Though the better solution is often splitting into smaller, more frequent SubQ doses.

Very low body fat. Men with extremely low subcutaneous fat (competitive bodybuilders in contest prep, for example) may not have adequate tissue depth for SubQ injection. If you can pinch less than 1/4 inch of skin and fat, SubQ becomes impractical.

Persistent SubQ nodules. A small percentage of patients develop firm, sometimes tender nodules at SubQ injection sites. If site rotation and volume reduction do not resolve this, switching to IM eliminates the issue.

Patient preference. Some men simply prefer IM after trying both. The data favors SubQ on average, but individual response varies. If your labs look good and you are comfortable with IM, there is no clinical reason to force a switch.

How to Switch from IM to SubQ

Switching is straightforward, but a few considerations matter:

Dose adjustment. Most clinics use the same dose when switching from IM to SubQ. However, because SubQ absorption is slower and steadier, some patients find they can achieve the same therapeutic levels at a slightly lower dose. Work with your clinic to check labs 6-8 weeks after switching.

Frequency. If you were injecting IM once weekly, you may benefit from splitting to twice weekly SubQ. The combination of SubQ's inherently steadier absorption plus increased frequency creates the flattest possible testosterone curve.

Expect a transition period. The first 2-3 weeks after switching may feel slightly different as your body adjusts to the new absorption pattern. Do not make dose changes based on how you feel during this transition -- wait for labs.

Keep your old supplies briefly. If you develop nodules or discomfort with SubQ, you can switch back to IM temporarily while troubleshooting site rotation and volume.

For a full comparison of delivery methods beyond injections, see our guide on types of TRT: injections, gels, pellets, and cream.

The Verdict

The evidence strongly favors subcutaneous injection for most TRT patients. SubQ delivers equivalent testosterone levels with better stability, lower estradiol conversion, lower hematocrit impact, less pain, easier self-administration, and no risk of hitting nerves or blood vessels.

The original pilot study on subcutaneous testosterone replacement, published in 2006, concluded that low-dose subcutaneous testosterone was a viable alternative to intramuscular injection for hypogonadal men [6]. Since then, every subsequent study has reinforced that finding, and the 2018 FDA approval of a subcutaneous testosterone product made it official.

If you are starting TRT, ask your clinic about subcutaneous protocols. If you are currently on IM and dealing with estradiol issues, hematocrit creep, injection anxiety, or energy crashes before your next shot, a switch to SubQ may resolve those problems without changing your dose.

The best injection method is the one that keeps your levels stable, your side effects minimal, and your adherence consistent. For most men, that is subcutaneous.

---

References

1. Fukami M, et al. Hormone profiles after intramuscular injection of testosterone enanthate in patients with hypogonadism. Endocrine Journal. 2006;53(3):305-310. PMID: 16710076

2. Kaminetsky J, et al. A 52-Week Study of Dose Adjusted Subcutaneous Testosterone Enanthate in Oil Self-Administered via Disposable Auto-Injector. Journal of Urology. 2019;201(3):587-594. PMID: 30296416

3. Olson J, et al. Serum Testosterone Concentrations Remain Stable Between Injections in Patients Receiving Subcutaneous Testosterone. Journal of the Endocrine Society. 2018;2(8):787-796. PMID: 29264562

4. Gittelman M, et al. Comparison of Outcomes for Hypogonadal Men Treated with Intramuscular Testosterone Cypionate versus Subcutaneous Testosterone Enanthate. Journal of Urology. 2022;207(3):677-683. PMID: 34694927

5. Spratt DI, et al. Subcutaneous Injection of Testosterone Is an Effective and Preferred Alternative to Intramuscular Injection: Demonstration in Female-to-Male Transgender Patients. Journal of Clinical Endocrinology & Metabolism. 2017;102(7):2349-2355. PMID: 28379417

6. Al-Futaisi AM, et al. Subcutaneous administration of testosterone. A pilot study report. Saudi Medical Journal. 2006;27(12):1843-1846. PMID: 17143361

7. McFarland J, et al. Testosterone Therapy With Subcutaneous Injections: A Safe, Practical, and Reasonable Option. Federal Practitioner. 2021;38(11):e8-e13. PMID: 34698352

8. Wilson DM, et al. Pharmacokinetics, safety, and patient acceptability of subcutaneous versus intramuscular testosterone injection for gender-affirming therapy: A pilot study. Transgender Health. 2018;3(1):174-180. PMID: 29367424